Muscle-invasive bladder carcinomas (MIBCs) are aggressive genitourinary malignancies. Disease incidence and survival rates vary based on aggressiveness and treatment options. Metastatic urothelial carcinoma of the bladder is generally incurable by current chemotherapy and leads to early mortality. For a minority (~20%) of patients, T-cell checkpoint inhibitors provide durable benefits following prior platinum therapy. Recent studies have identified molecular subtypes of MIBCs with different sensitivities to frontline therapy, suggesting heterogeneity in these tumors and pointing to the importance of molecular characterization of MIBCs to provide effective treatment. We have performed multi-omic profiling of the kinome to identify therapeutic targets that are overexpressed in a subset of BLCAs. Our analyses revealed amplification and overexpression of P21 (RAC1) activated kinase 4 (PAK4) in a subset of BLCAs. For these tumors, multiplex kinase assay profiling identified corresponding PAK4 target substrates. By performing experiments using cultured bladder cancer cells, we confirmed the role of PAK4 in BLCA cell proliferation and invasion. Furthermore, our studies showed that a PAK4 inhibitor was effective in curtailing growth of BLCA cells. Transcriptomic analyses identified elevated expression of another kinase, Protein Tyrosine Kinase 6 (PTK6), upon treatment with a PAK4 inhibitor.
Introduction
Bladder cancer (BLCA) is the ninth-most common malignancy worldwide (1) . Most BLCAs are urothelial carcinomas, and metastatic urothelial carcinoma is generally incurable by current cisplatin-based first-line chemotherapy, leading to early mortality (2) . Perioperative cisplatin-based combination chemotherapy for localized muscle-invasive BLCA (MIBC) modestly improves survival; however, approximately half of all patients progress rapidly with distant metastatic disease (3, 4) . For a minority (~20%) of patients with prior platinum therapy, T-cell checkpoint inhibitors have recently provided durable benefits as first-line therapy for cisplatinineligible patients with high tumor PD-L1 protein expression (5) (6) (7) (8) (9) (10) . Ongoing clinical trials are evaluating the combination of PD1/PD-L1 inhibitors with platinum-based first-line chemotherapy or with CTLA-4 inhibitors. Given the molecular heterogeneity of this disease, rational therapeutic targeting guided by somatic genomic alterations may hold promise.
Various molecular alterations are involved in the progression of aggressive BLCAs. Recent studies have identified, for MIBCs, molecular subtypes based on gene expression that have different sensitivities to frontline therapy, suggesting heterogeneity in these tumors and the importance of molecular characterization of the cancers to provide effective treatment (11) (12) (13) (14) . Dysregulation of the transcriptional maintenance system is believed to be a cause for malignancy (15, 16) . The advent of new technologies allows molecular analyses of BLCAs and enhances the promise of targeted therapy and personalized medicine (17, 18) .
Kinases, which are common drivers of malignancies, are potentially actionable for therapy. Kinase inhibitors, which are readily manufactured, are approved to treat various malignancies. Inhibitors of fibroblast growth factor receptor (FGFR), ERBB2, and mTOR kinase have activity against tumors harboring genomic alterations in their respective genes (19) (20) (21) . However, the primary kinase drivers of growth of urothelial carcinomas are unclear. Thus, we performed genomic, transcriptomic, and kinomic analyses of MIBC to identify aberrations in the kinome.
Results:
Multi-platform kinase analysis of tumor and normal samples identifies PAK4 as the primary amplified and overexpressed kinase gene.
Targeted kinome gene sequencing of 24 MIBC samples and their matched normal tissues led to identification of somatic mutations/indels and somatic copy number alterations. Overall, 24 kinases harbored somatic mutations/indels in two or more MIBC samples. TTN, OBSCN, EPHA5, FASTK, and MAST1 were most frequently mutated. For these samples, copy number analyses found PAK6, TTN, NEK1, and CDK17 to be predominantly deleted (≥4 of 24); RIPK3, PAK4, and TTBK2 were predominantly amplified (≥2 of 24) (Figure 1A,B) . Fluorescence in situ hybridization (FISH) using a PAK4 locus-specific probe revealed copy number gains in BLCA cells ( Figure 1C) . Kinase gene expression estimated by NanoString assays was analyzed for all frequently mutated/altered genes found by kinome sequencing analysis. Among the amplified 
TCGA validation confirms PAK4 as an alteration in MIBC associated with higher stage and worse outcomes.
We validated the most frequently amplified/deleted kinases (PAK6, TTN, NEK1, CDK17, RIPK3, PAK4, and TTBK2) using TCGA BLCA dataset via cBioPortal (Supplementary Figure 1A,B) .
PAK4 emerged as a biologically plausible driver gene, with 5% of TCGA BLCAs showing copy number amplification. Most PAK4-amplified TCGA BLCA samples (13 of 20) were of the luminal molecular subtype (luminal/luminal_papillary/luminal_infiltrated) ( Supplementary Table 1 ). We also observed elevated expression of PAK4 in distinct histological, molecular subtypes and in advanced stages of the samples (Figure 2A, Supplementary Figure 1C -E). This was confirmed by qRT-PCR using MIBC RNA and normal bladder tissue RNA (n=11) (Figure 2B ). There was also poorer survival (Log Rank P-value: 0.0473) of patients with PAK4 alterations [amplification/mRNA dysregulation] in BLCAs ( Supplementary Figure 2A) . Immunoblot analyses using PAK4 antibody showed that PAK4 protein expression was generally higher in BLCAs compared to normal bladder tissue ( Figure 2C) . We highlighted the PAK4-specific band, which was identified by the molecular weight and siRNA knockdown in bladder cells and by immunoblotting. Since the antibody produces multiple bands, we confirmed the specific band with PAK4 knockdown in VM-CUB1 cells (Figure 2C , right panels). We also measured PAK4 RNA and protein expression using various BLCA cell lines (Figure 2D ,E).
Kinase assays show increased activity in BLCAs overexpressing PAK4.
As kinases are frequently regulated post-transcriptionallyand their activity plays a key role, we measured kinase activity in tumor samples by an enzymatic kinomic assay and found phosphorylation changes for the four identified PAK4 substrates (Figure 3A) , which were altered inter-patient between paired normal-tumor tissues ( Figure 3B ). Of the 24 patient tumors, 8 (33%) had high PKAS values (>2.0) ( Figure 3C ). For copy number variations (CNVs), 3 (37.5%) had amplifications, with two large-scale and one focal amplification.
PAK4 is involved in bladder cancer cell growth, invasion, and colony formation.
Next, to investigate the role of PAK4 kinase in BLCA biology, we performed transient PAK4 knockdown in VM-CUB1 and RT-112 cells using two independent and specific siRNAs. To confirm the knockdown efficiency, we performed immunoblot analysis using protein lysates prepared after 72 hours of transient transfection (Figure 4A-B, inset) . We evaluated cell proliferation, invasion, and colony formation using control and PAK4-knockdown cells. The cell proliferation assay using PAK4 knockdown cells indicated lower cell numbers (Figures 4A-B ).
VM-CUB1 cells with PAK4 knockdown showed less invasive potential in Boyden chamber
Matrigel invasion assays ( Figure 4C ). (Note: One of the siRNAs did not show any phenotypic changesin RT-112 cells). Additionally, cells with PAK4 knockdown showed less colony formation ( Figure 4D) . These observations indicate an essential role for PAK4 in proliferation, invasion, and colony formation of BLCA cells.
MicroRNAs miR-122 and miR-193 are involved in regulation of PAK4 expression.
In addition to PAK4 amplification in 12% of BLCAs, there was upregulation of PAK4 in 50% of MIBCs. Hence, to test other forms of regulation, we investigated microRNAs that might target PAK4. Our analyses using Targetscan (22) suggested that microRNA-122 and 193 had binding sites at the 3'UTR of PAK4 (Supplementary Figure 3A) . In various cancers, microRNA-122 and 193 are downregulated through epigenetic mechanisms (23) (24) (25) (26) . When these microRNAs were introduced into VM-CUB1 and RT-112 cells, there was downregulation of PAK4 expression (Supplementary Figure 3B) ; this was not caused by control microRNAs. Furthermore, addition of the microRNAs reduced colony formation (Supplementary Figure 3C) . Thus, in a subset of bladder cancers, downregulation of PAK4 regulating microRNAs could lead to PAK4 overexpression.
The PAK4 inhibitor reduces bladder cancer cell proliferation and colony formation.
To evaluate the effect of PAK4 inhibition by a small molecule targeting PAK4, we performed proliferation and colony formation assays with VM-CUB1 and RT-112 cells that were untreated, treated with vehicle control, or treated with the PAK4 inhibitor (vandetanib) at various concentrations for 6 days. In the presence of the inhibitor, there was less cell proliferation ( Figure   5A -B). Further, PAK4 at nanomolar concentrations reduced colony formation ( Figure 5C ). (Note that the degree of specificity of vandetanib for PAK4 could vary, as is the case for other kinase inhibitors). These results show that, for BLCAs, inhibition of PAK4 could be effective in reducing or blocking cancer growth.
The global effects of PAK4 inhibition and PAK4 knockdown on bladder cancercells.
To identify downstream targets of PAK4, whole transcriptome sequencing (RNA-seq) of VM- up-regulated (186 protein-coding) and 173 down-regulated (164 protein-coding) genes were identified from differential expression analysis of cells treated with PAK4 siRNA relative to NT siRNA (Supplementary Table 2 ). Those with absolute fold changes of ≥1.5 and P-values <0.05 were selected as differentially expressed genes [DEG] (Figure 6 A) . Comparison of protein-coding DEGs from PAK4-inhibitor treated cells and PAK4 siRNA-treated cells showed 10 commonly upregulated and 26 commonly down-regulated genes (Figure 6B ).
PAK4 inhibition and PAK4 knockdown induces increased expression of PTK6.
On PAK4 inhibition and knockdown, there was greater expression of PTK6, an oncogene (27) .
With additional treatment with a PTK6 inhibitor (dasatinib) after PAK4 inhibition, there was less cell proliferation as compared to inhibition with PAK4 or PTK6 alone ( Figure 7A Table 3 ). Genes upregulated by EZH2 (C3, CXCL8, CYP1B1, BIRC3, SLC1A3, PCDHB5, NFKBIA, MPZL2, and LCN2) were down-regulated; DKK1, which is down-regulated by EZH2, showed over-expression ( Supplementary Figure 2B ).
Protein-protein interaction analysis reveals primary interactors affected by PAK4
inhibition/knockdown. Among the 620 differentially expressed genes in both/either of the treatments, 331 proteins were found to be interacting with 1122 connections with a confidence threshold of 0.5. The core interaction network included 277 proteins with 1085 edges (Supplementary Figure 5 ). PAK4 may directly interact (primary interactors) with six proteins (LAMA3, LAMB3, LAMC2, MAP2K1, SH3PXD2A, and RHOD). Among these, only SH3PXD2A was up-regulated upon siRNA-based knockdown of PAK4, whereas the other five were up-regulated by treatment with the inhibitor. Of these six, PAK4 interactions with three laminin proteins (LAMA3, LAMB3, and LAMC2) had a high confidence of 0.9. Five of the primary interactors (LAMA3, LAMB3, LAMC2, SH3PXD2A, and RHOD) were mainly involved in cell junction assembly. The results showed 17 proteins interacting with the six primary interactors. Most of these directly or indirectly interacting proteins were cell adhesion molecules. Except for CDK1, DEPDC1B, and ITGB8, all the primary and secondary interactors were up-regulated in response to one or both treatments. CDK1 and DEPDC1B were down-regulated by siRNA-based knockdown, whereas ITGB8 showed contradicting regulation, i.e., up-regulated by siRNA-based knockdown and downregulated by inhibitor treatment. Manual inspection of the network showed four distinct protein hubs. Hub1 contained 19 proteins, of which 18 were significantly (q=6.80E-23) associated with translation processes. Hub2 was dominated by histone proteins representing the DNA packaging process (q=8.237E-39). The third hub of 32 proteins was enriched for cell cycle process (q=6.642E-26). Hub4 contained 20 proteins; the DNA repair process was enriched (q=7.34E-16).
These in silico analyses provide a rationale to test some of the potential additional network genes to evaluate their role in PAK4-mediated activity in bladder cancer.
Discussion
Identification of additional targets for therapy of MIBC is essential. In the present study, we explored the kinome of BLCA using various omic technologies including kinomic, NanoString, and RNA-sequencing. Our study identified PAK4 as amplified and overexpressed in up to 12% of bladder cancers. Using various methods, we confirmed amplification and overexpression of PAK4 with high PAK4-related kinomic activity. Furthermore, our results suggested a role for PAK4 in BLCA progression; targeting it in BLCA cells reduced cell proliferation. Thus, BLCAs often present with PAK4 overexpression, and inhibition of PAK4 reduces proliferation, colony formation, and invasion of BLCA cells.
PAK4 belongs to a family of serine/threonine kinases that are involved in cell proliferation and migration and in cytoskeletal organization. PAK4 is amplified/over-expressed in non-Hodgkin lymphoma (28) , esophageal cancer (29, 30) , pancreatic cancer (31) (32) (33) (34) (35) , breast cancer (36, 37) , and other cancers (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) . Activated PAK4 a) promotes tumorigenesis in breast cancer via activation of the PI3K/AKT signaling pathway (48), b) promotes liver metastasis by phosphorylation of p53 (49) , and c) facilitates the epithelial-mesenchymal transition [EMT] in prostate cancer via phosphorylation of the Slug transcription factor (50) . Elevated nuclear localization of PAK4 influences breast-to-bone metastasis by targeting the metastasis suppressor, LIFR (51) . Targeting of PAK4 via miRNAs, including miR-199a/b-3p (30, 39, 40, 44) , miR-485 (41), miR-342 (52), miR-145 (53, 54) , miR-24-1-5p (55), miR-224 (56), miR-126 (44) , and miR-433 (57) suppresses cancer cell proliferation and migration.
Although BLCA, particularly MIBC, is treated with perioperative cisplatin-based combination chemotherapy, the improvement in survival is modest (3, 4) . Within 2 years, systemic dissemination occurs in ~50% of all MIBC patients. Metastatic urothelial carcinoma is generally incurable with cisplatin-based chemotherapy, yielding a median survival of 12 to 15 months.
Although PD1/PD-L1 inhibitors provide durable responses for 15 to 25% of patients, the median survival of patients receiving cisplatin-based chemotherapy is less than one year (8) . Given the molecular heterogeneity of the disease, rational drug development targeting molecular subgroups of patients is warranted. FGFR inhibitors have activity for patients with FGFR3-altered metastatic urothelial carcinomas, although, to yield durable benefits, an additional drug, potentially a PI3K inhibitor, may be required (58) . Similarly, melanomas with BRAF-activating mutations demonstrate sensitivity to a combination of RAK and MEK inhibitors (59) . The present studies showed that inhibition of PAK4, particularly in combination with a PTK6 inhibitor, is an effective therapy for the sub-set of BLCAs with PAK4 amplification or overexpression. Moreover, based on gene expression, the luminal TCGA intrinsic subtype I was enriched for PAK4 amplification and may provide a surrogate predictive marker for benefit from inhibiting PAK4.
Kinase activity profiling identified BLCAs with high PAK4 activity scores despite not having amplification. This indicates that, since kinases are frequently regulated post-transcriptionally and are activated independently, therapeutic target identification should be assessed at various biological levels (i.e., CNVs, kinase activity). PAK4 alterations occurred in 12.5-33% of the analyzed MIBCs.
We have shown that bladder cancer presents with overexpression of PAK4 and that inhibition of PAK4 inhibits the cancer phenotypes. Since many drugs engender resistance to treatments, it is necessary to assess possible downstream effects that may be induced by a therapeutic. Here, by performing sequencing of RNA from PAK4-inhibited cells, we identified activation of PTK6, a non-receptor tyrosine kinase that is overexpressed in BLCA and contributes to a poor prognosis (27) . Furthermore, treatment with a PTK6 inhibitor after PAK4 inhibition caused a reduction in cell proliferation as compared to PAK4 or PTK6 inhibition alone. Together, the data support a potential therapeutic advantage of combination therapy with PAK4 and PTK6 inhibitors for patients with BLCAs overexpressing PAK4.
In summary, the present results provide evidence for overexpression of PAK4 in a subset of MIBCs. Further, PAK4 inhibition leads to upregulation of PTK6, and targeting both of these kinases reduces BLCA cell growth (Figure 7C) . Future studies will involve use of PAK4overexpressing BLCA patient-derived xenografts to evaluate the efficacy of PAK4 and PTK6 inhibitors in reducing BLCA growth. For selected patients, further preclinical validation and clinical trials are warranted for this potentially actionable therapeutic target. 
Material and Methods:

Patient and tumor selection
Harvesting of DNA and RNA from tissue
Tumors and normal tissues were isolated to provide genomic DNA and RNA. Genomic DNA was isolated using phenol-chloroform extraction by standard techniques and quantified by Qubit Broad Range dsDNA kits (Invitrogen, Carlsbad, CA). DNA quality was assessed by gel electrophoresis.
RNA was harvested by employing Qiagen RNAeasy kits, and its quality was evaluated by the 260/280 ratio using NanoDrop (Thermo Fisher Scientific). Varscan2 was used to identify somatic copy number alterations in each BLCA by comparing with matched normal tissue. Using mpileup from Samtools (69) and the copy number method from varscan2, raw copy number calls were obtained from BAM files for each normal and tumor pair.
Targeted kinome sequencing and data analysis
Next, the Copycaller method from Varscan2 was used to adjust raw copy number calls to GC content. This was followed by application of circular binary segmentation using R package 'DNAcopy'. Finally, adjacent segments with similar copy numbers were merged and classified based on size (large-scale or focal). Circos plots depicting results of kinome sequencing analysis were generated using Circos software (70) . Targeted kinome sequencing data have been submitted to the NCBI Sequence Read Archive (SRA) [Accession ID: PRJNA548509].
Kinase gene expression assay on the NanoString platform
Expression profiling of 519 kinase genes and 8 housekeeping genes was measured using the NanoString nCounter® analysis system (71) . RNA was hybridized for 19 hours at 65 0 C in the nCounter® NanoString platform, followed by digital counting utilizing two hybridizing base probes per RNA. A codeset specific to a 100-base region per RNA, which used a 3' biotinylated capture probe and a 5' reporter probe tagged with a fluorescent barcode, was employed. Figure 3A) . For each peptide, the ranking of PAK4 at the time of analysis was as follows: CFTR_730_742 (11 th ), NMDZ1_890_902 (12 th ), KS6A1_374_386 (14 th ), and TOP2A_1463_1475 (14 th 
RNA-seq data analysis
Raw sequencing data comprising 50bp paired-end reads were cleaned using Trim Galore (v0 RNA-seq data were uploaded to the NCBI Gene Expression Omnibus [GEO, #GSE130455].
Pathway and upstream regulator analysis
In VM-CUB1 cells after PAK4 inhibitor or PAK4 siRNA treatment, canonical pathways enriched by DEGs were identified separately using the Ingenuity Pathway Analysis (IPA) Core analysis module. Similarly, IPA upstream regulator analysis was used to identify potential upstream regulators of DEGs.
Cell culture
The bladder cancer cell lines HT1197 (ATCC), HT1376 (ATCC), VM-CUB1 (DSMZ), and KU- FBS with 100 U/ml penicillin-streptomycin in a 5% CO2 cell culture incubator.
Benign and Tumor Tissues
As described earlier (80), we utilized formalin-fixed paraffin-embedded tissues, both normal tissues and clinically localized BLCAs. Supplementary Table 4 
Cell Proliferation
Cell proliferation assays were conducted for siRNA-treated cells and measured by cell counting.
Cells with transient or stable PAK4 knock down were plated at 10,000 cells/well in 12-well plates (n = 3). Cells were harvested and, at indicated time points, counted with a Coulter counter (Beckman Coulter, Fullerton, CA). Cells treated with NT siRNA served as controls. Samples were tested in triplicate.
Cell Viability Assays
Western Blot Analyses
Immunoblot analyses were performed as described earlier (80) . 
Matrigel Invasion Assays
Matrigel invasion assays were performed as described earlier (80) (81) (82) . Briefly, cells were seeded onto Corning BioCoat Matrigel matrices (# 08-774-122, Corning, New York, NY) in the upper chambers of 24-well culture plates without FBS. The lower chambers contained the respective medium supplemented with 10% FBS as a chemoattractant. After 48 hours, the non-invading cells and the Matrigel matrices were removed with cotton swabs. Invasive cells located on the lower sides of the chambers were stained with 0.2% crystal violet in methanol, air-dried, and photographed using an inverted microscope (4×). Invasion was quantified by a colorimetric assay.
For this, the inserts were treated with 150 μl of 10% acetic acid, and absorbance was measured at 560 nm.
Colony Formation Assays
Colony formation assays were performed as described earlier (80) . Transient, stable knockdown, or inhibitor-treated cells were counted and seeded as 1000 cells per well of 6-well plates (triplicates) and incubated at 37°C, with 5% CO2, for 10-15 days. Colonies were fixed with 10%
(v/v) glutaraldehyde for 30 minutes and stained with crystal violet (Sigma-Aldrich, St. Louis, MO) for 20 minutes. Then, photographs of the colonies were taken using an Amersham Imager 600RGB
(GE Healthcare Life Sciences, Pittsburgh, PA).
Protein-protein interaction network analysis
The differentially expressed genes obtained by sequencing of RNA for VM-CUB1 cells treated with PAK4 inhibitor or siRNA against PAK4 were used for generation of protein interaction networks. The protein interactions among differential genes were retrieved from the STRING database (83) . The search was restricted to interactions with 'experimental' evidence and from 'databases', and a minimum confidence threshold of 0.5 was applied. The obtained interactions were then submitted to Cytoscape network analysis (84) for visualization and analysis. The protein interaction network was manually inspected to extract the hubs of densely interacting proteins.
The functional analysis and enrichment of the protein-protein interaction network was performed using the KEGG database (85), ToppGene Suite (86), and TRRUST database (87) .
Statistical analyses
Coefficients of drug interaction (CDIs) were calculated with the equation CDI = AB/(A × B).
Briefly, the relative cell viability of the combination (AB) was divided by the relative cell viabilities of the single agents multiplied. CDI < 1 indicated a synergistic effect; CDI = 1 indicated an additive effect; and CDI > 1 indicated an antagonistic effect. This calculation was performed for each set of drug concentrations (88) . The authors thank Dr. Donald Hill for critical reading and editing of this manuscript. Genes that were similarly affected by PAK4 knockdown and PAK4 inhibition in VM-CUB1 cells are depicted in a heatmap generated using "ggplots" R package. CALML3  TM7SF2  FLNB  ADAM8  KRT6A  PTK6  ABCA7  PDGFB  SERPINI1  SEMA7A   PAK4  CDCA7  C3  CSF1  MYBL2  WDR76  HIST1H2AL  E2F8  HIST1H1D  HIST1H3D  PTGS1  DTL  HIST1H4A  HIST1H4D  DUT  HIST1H1B  DSN1  HIST1H4C  ZWINT  CEP78  TK1  HIST1H3B  HIST1H2BI 
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